Physician profile
Kanika Kaur
NPI 1760629919
$6,573.39
in general payments reported to CMS, 2019-2025
25 companies · $2,258 in 2025
The $2,258 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $240 · 2021: $553 · 2022: $1,012 · 2023: $760 · 2024: $1,354 · 2025: $2,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,288 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,287.84 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,230.97 | 2019-2025 | |
| Janssen Biotech, INC. | $677.66 | 2020-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $549.88 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $412.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $370.59 | 2021-2022 | |
| Pfizer INC. | $263.18 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.13 | 2020-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $232.03 | 2024-2025 | Ibsrela |
| Redhill Biopharma INC. | $207.64 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Regeneron Healthcare Solutions, INC. | $183.31 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $169.26 | 2019-2024 | Dificid |
| Boston Scientific Corporation | $155.93 | 2025 | Axios |
| Lilly USA, LLC | $134.75 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Genzyme Corporation | $113.42 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $110.79 | 2021 | |
| Phathom Pharmaceuticals, INC. | $109.06 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $59.47 | 2022-2023 | Ocaliva |
| Celgene Corporation | $49.48 | 2022-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $47.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $28.55 | 2025 | |
| Aimmune Therapeutics, INC. | $24.10 | 2025 | Zenpep |
| Allergan, INC. | $22.45 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.55 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanika Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.